Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Guangjun Jing"'
Autor:
Zhonglian Cao, Hui Zhao, Jiajun Fan, Yilan Shen, Lei Han, Guangjun Jing, Xian Zeng, Xin Jin, Zeguo Zhu, Qi Bian, Yanyang Nan, Xiaozhi Hu, Xiaobin Mei, Dianwen Ju, Ping Yang
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract The pathogenesis of diabetic kidney disease (DKD) is complicated. Current clinical treatments fail to achieve satisfactory efficacy in the prevention of DKD progression, it urgently needs novel and effective treatment for DKD. In this study,
Externí odkaz:
https://doaj.org/article/0de5f18b146b4cb391f39ab3c1f381b1
Autor:
Xiaozhi Hu, Jiajun Fan, Qianqian Ma, Lei Han, Zhonglian Cao, Caili Xu, Jingyun Luan, Guangjun Jing, Yanyang Nan, Tao Wu, Yuting Zhang, Hanqi Wang, Yuanzhen Zhang, Dianwen Ju
Publikováno v:
Journal of Nanobiotechnology, Vol 20, Iss 1, Pp 1-17 (2022)
Abstract Background Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease mainly on account of hypercholesterolemia and may progress to cirrhosis and hepatocellular carcinoma. The discovery of effective therapy for NAFLD is an essential unm
Externí odkaz:
https://doaj.org/article/5dbeba4e36234562bc58ecedb43f8322
Autor:
Ming Shi, Li Li, Shiyuan Wang, Hai Cheng, Wei Chen, Wei Sang, Kunming Qi, Zhenyu Li, Gang Wang, Huizhong Li, Jianping Lan, Jinqi Huang, Xiaoming Fei, Min Yu, Fei Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Guangjun Jing, Junnian Zheng, Robert Peter Gale, Kailin Xu, Jiang Cao
Publikováno v:
American Journal of Hematology. 97:711-718
CD19-targeted chimeric antigen receptor T (CAR-T) cells using murine single-chain variable fragment (scFv) has shown substantial clinical efficacy in treating relapsed/refractory acute lymphoblastic leukemia (R/R ALL). However, potential immunogenici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3d5fe08c46dea59eff12d96611d6687
https://doi.org/10.1002/ajh.26506
https://doi.org/10.1002/ajh.26506
Autor:
Guangjun Jing, Hai Cheng, Kailin Xu, Kunming Qi, Bin Pan, Wei Sang, Ping Li, Xi Zhang, Ying Wang, Jieyun Xia, Zhiling Yan, Xiangmin Wang, Junnian Zheng, Jiang Cao, Feng Zhu, Ming Shi, Aibin Liang, Zhenyu Li, Hujun Li, Chunrui Li, Haiying Sun, Xu Tan, Jianfeng Zhou, Depeng Li
Publikováno v:
Blood Advances. 5:5290-5299
Systematic and dynamic humoral immune reconstitution is little-known for patients with relapsed/refractory (R/R) multiple myeloma (MM) who received anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy. We investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be8ca091b9ccd70dd3c7786a6a916920
https://doi.org/10.1182/bloodadvances.2021004603
https://doi.org/10.1182/bloodadvances.2021004603
Autor:
Ying Wang, Jiang Cao, Weiying Gu, Ming Shi, Jianping Lan, Zhiling Yan, Lai Jin, Jieyun Xia, Sha Ma, Yang Liu, Hujun Li, Bin Pan, Wei Chen, Xiaoming Fei, Chunling Wang, Xiaobao Xie, Liang Yu, Gang Wang, Huizhong Li, Guangjun Jing, Hai Cheng, Feng Zhu, Haiying Sun, Wei Sang, Depeng Li, Zhenyu Li, Junnian Zheng, Kailin Xu
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(20)
PURPOSE A combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric antigen receptor (CAR) T cells induced high response rates in patients with relapsed or refractory (R/R) multiple myeloma (MM), but long-term outcomes have not be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7af7b13bf90a83cd3004741f87bfacc
https://pubmed.ncbi.nlm.nih.gov/35414660
https://pubmed.ncbi.nlm.nih.gov/35414660
Autor:
Jianping Lan, Zhenyu Li, Hai Cheng, Ming Shi, Wei Sang, Zhiling Yan, Wei Chen, Ying Wang, Lai Jin, Jianlin Qiao, Jing Zhao, Kailin Xu, Xiaoming Fei, Huanxin Zhang, Jiang Cao, Qing-Yun Wu, Junnian Zheng, Feng Zhu, Gang Wang, Yao Yao, Guangjun Jing
Publikováno v:
The Lancet Haematology. 6:e521-e529
Summary Background Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has been shown to have activity in patients with relapsed or refractory multiple myeloma. Reports have suggested that a small subgroup of less dif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5faf796530bb26e572e0c6bbbebc5ced
https://doi.org/10.1016/s2352-3026(19)30115-2
https://doi.org/10.1016/s2352-3026(19)30115-2
Publikováno v:
Journal of Cancer
Thyroid cancer remains a significant health problem worldwide. Traditional chemotherapy does generate long-term benefit but are usually accompanied by severe side effects. Immunotherapy by adoptive infusion of T cells is now an attractive alternative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd961637667ee049d0da1f053916ab47
https://doi.org/10.7150/jca.30163
https://doi.org/10.7150/jca.30163
Autor:
Guangjun Jing, Chun-Ying Ye, Kailin Xu, Hai Cheng, Wei Chen, Lingyu Zeng, Junnian Zheng, Gang Wang, Kunming Qi, Ming Shi, Shi-Yuan Wang, Zhenyu Li, Jiang Cao, Qing-Yun Wu, Xue Wang
Publikováno v:
American Journal of Hematology. 96
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c6eb9df228015278d0678294307902e
https://doi.org/10.1002/ajh.26123
https://doi.org/10.1002/ajh.26123
Autor:
Guangjun Jing, Ying Wang, Yang Liu, Xi Zhang, Xue Wang, Kunming Qi, Hai Cheng, Wei Sang, Zhiling Yan, Bin Pan, Robert Peter Gale, Jian Ge, Xu Tan, Ming Shi, Jianlin Qiao, Junnian Zheng, Kailin Xu, Jiang Cao, Feng Zhu, Zhenyu Li, Ruixiang Xia
Publikováno v:
Leukemia. 34(10)
Chimeric antigen receptor (CAR)-T-cell is a safe and effective therapy of B-cell cancers but it is unknown if this is so in persons with prior hepatitis B virus (HBV) infection. We studied 70 subjects with advanced B-cell cancers receiving CAR-T-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f58fd72df1c94f19a1b47bf2315ac0
https://pubmed.ncbi.nlm.nih.gov/32594100
https://pubmed.ncbi.nlm.nih.gov/32594100
Autor:
Kunming Qi, Jianlin Qiao, Qing-Yun Wu, Bin Pan, Guangjun Jing, Gang Wang, Hai Cheng, Junnian Zheng, Li Zhenyu, Kailin Xu, Wei Sang, Huizhong Li, Jiang Cao, Ming Shi, Jing Zhao, Mingshan Niu, Lingyu Zeng, Chen Wei
Publikováno v:
American Journal of Hematology. 93:851-858
Chimeric antigen receptor T (CAR-T) cell therapy has shown promising results for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). The immune response induced by murine single-chain variable fragment (scFv) of the CAR may limit CAR-T cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25d78b6cd4dc78b0ea161c0e65c0e027
https://doi.org/10.1002/ajh.25108
https://doi.org/10.1002/ajh.25108